Panel Discussion – Preclinical and Clinical Adenosine Receptor Targeting
Time: 2:30 pm
day: Day Two
Details:
- Discuss therapeutic and strategic strengths of single receptor targeting vs dual inhibition
- Examine which aspects of A2AR and A2BR make it a better or worse target than CD73/39
